Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Junshi Biosciences Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab September 24, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates August 30, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma August 12, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab July 26, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma July 17, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC June 25, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer June 18, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint June 11, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab April 24, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer April 07, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates March 29, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority February 01, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer January 17, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine January 09, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients January 02, 2024 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA December 01, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19 November 22, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 October 27, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates August 30, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer July 19, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab July 11, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer June 29, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer May 23, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries May 07, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma April 27, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study April 20, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint April 11, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients April 11, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates March 31, 2023 From Junshi Biosciences Via GlobeNewswire Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia March 28, 2023 From Junshi Biosciences Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.